1. Home
  2. RAND vs LSTA Comparison

RAND vs LSTA Comparison

Compare RAND & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$10.28

Market Cap

31.8M

Sector

Finance

ML Signal

HOLD

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$3.54

Market Cap

28.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
LSTA
Founded
1969
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Misc Health and Biotechnology Services
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.8M
28.9M
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
RAND
LSTA
Price
$10.28
$3.54
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
3.6K
98.6K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
10.83%
N/A
EPS Growth
N/A
20.42
EPS
N/A
N/A
Revenue
N/A
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
56.90
52 Week Low
$10.00
$1.81
52 Week High
$20.00
$5.07

Technical Indicators

Market Signals
Indicator
RAND
LSTA
Relative Strength Index (RSI) 42.97 53.53
Support Level $10.03 $3.06
Resistance Level $11.15 $3.67
Average True Range (ATR) 0.15 0.17
MACD 0.00 0.02
Stochastic Oscillator 34.99 29.73

Price Performance

Historical Comparison
RAND
LSTA

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: